Blood-Brain Barrier Market Revenue to Cross USD 2.90 billion by 2035

Published: May 2024


According to a recently published report by Roots Analysis, the increasing prevalence of CNS disorders, and rising demand for blood-brain barrier penetrating drugs are driving the blood-brain barrier market.

Blood-Brain Barrier Industry Overview

The global blood-brain barrier market is anticipated to grow at a CAGR of 49% from 2024-2035, reaching USD 2.90 billion by 2035.

BBB is a highly selective and semipermeable micro-vessel network between blood and the brain. The unique barrier prevents harmful substances from reaching the brain while allows essential nutrients and molecules to pass through it. BBB is highly selective in nature and only allows (mostly by passive diffusion) the passage of lipid soluble molecules, water, certain gases and transport of molecules, such as glucose and amino acids, which are essential for neural functions and regulation of CNS homeostasis. Approximately 98% of small molecule and all large molecule drugs are excluded from the brain to protect the CNS from any potential toxins, pathogens, inflammation, injury, and disease.

Browse 200+ figures and 195+ market data tables spread across 375+ pages and detailed Table of Content on “Blood-Brain Barrier Market, till 2035 by Type of Molecule (Biologics and Small Molecules), Route of Administration (Intravenous and Oral), Target Disease Indication (Amyotrophic Lateral Sclerosis, Leptomeningeal Carcinomatosis, Mucopolysaccharidosis Type II (Hunter Syndrome), Mucopolysaccharidosis Type III A (Sanfilippo Syndrome A) and Multiple Sclerosis) and Therapeutic Area (Lysosomal Storage Disorders, Neurodegenerative Disorders and Neuro-Oncology Disorders), and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)” Here: https://www.rootsanalysis.com/reports/blood-brain-barrier-drug-delivery/310.html

Market Drivers

Given the rising prevalence of neurological disorders, the blood-brain barrier market is anticipated to grow significantly over the coming years. Notably, there are several companies which are exploring novel technologies and are heavily investing in the development of unique and effective BBB penetrating drug candidates. Further, the integration of nanotechnology, targeted drug delivery systems and the development of novel drug formulations is driving the technological advancements in the blood brain barrier domain. The development of such technologies is anticipated to transform the landscape of neurodegenerative disorders.

Market Restraints

While the blood-brain barrier market is experiencing substantial growth, there are certain restraints that can hinder the growth of the industry. One of the primary factors include significant market competition in this domain. Various researchers and companies are likely to develop novel technologies in-house to stay at the forefront, thereby, posing a significant challenge for the drug developers in the foreseeable future. Further, a substantial financial investment is required for the research, development, and production of blood-brain barrier penetrating technologies and drugs. Moreover, the approval process involves stringent regulatory standards to guarantee safety, effectiveness, and quality.

Growth Factors

Despite the aforementioned challenges, various growth factors continue to drive the growth in blood-brain barrier market. One of the primary factors include the rising incidence of neurological disorders, demographic shifts towards an aging population, and escalating healthcare expenditure, globally. Further, BBB-penetrating technologies facilitate precise drug delivery to distinct areas in the brain, tailored to individual patient characteristics, in the coming years. Additionally, by leveraging advancements in drug delivery technologies and molecular diagnostics, pharmaceutical companies can capitalize on this opportunity to develop targeted therapies tailored to the unique needs of patients.

Blood-Brain Barrier Market Segments

Based on the type of molecule, the market is segmented into biologics and small molecules.

  • The biologics segment led the blood-brain barrier market, capturing the largest revenue in 2024.
  • Further, the small molecules segment is anticipated to witness the highest market growth rate of 31.9%, annually, during the forecast period. 

Based on the route of administration, the market is segmented into oral and intravenous.

  • The intravenous segment led the blood-brain barrier market, capturing the largest revenue in 2024.
  • The oral segment is anticipated to witness the highest market growth rate of around 31.9%, annually, during the forecast period.

Based on the target disease indication, the market is segmented into multiple sclerosis, mucopolysaccharidosis type II (hunter syndrome), amyotrophic lateral sclerosis, leptomeningeal carcinomatosis and mucopolysaccharidosis type III A (sanfilippo syndrome A).

  • The Mucopolysaccharidosis Type II (Hunter Syndrome) segment led the blood-brain barrier market, capturing the largest revenue in 2024. 
  • Further, multiple sclerosis disease is anticipated to witness the highest market growth rate of 29.2% annually, during the forecast period. 

Based on the therapeutic area, the market is segmented into neurodegenerative disorders, lysosomal storage disorders and neuro-oncology disorders.

  • The lysosomal storage disorders segment led the blood-brain barrier market, capturing the largest revenue in 2024. 
  • Further, neurodegenerative disorders is anticipated to witness the highest market growth rate of 31.9% annually, during the forecast period.  

Based on the Regional Insights, the market is segmented North America, Europe, Asia-Pacific and Rest of the World

  • Asia-Pacific and Rest of the World dominated the blood-brain barrier market and accounted for the largest revenue in 2024.
  • In North America, the blood-brain barrier market is market is anticipated to demonstrate lucrative growth of 29%, during the forecast period.

Blood-Brain Barrier Market Key Companies Profiled 

The blood-brain barrier market report also includes detailed profiles of key players (listed below) that offer blood-brain barrier drugs and technologies:

  • Angiochem
  • biOasis Technologies
  • CERES BRAIN Therapeutics
  • Cyclenium Pharma
  • Denali Therapeutics
  • Genervon Biopharmaceuticals
  • ICBI
  • JCR Pharmaceuticals
  • Lauren Sciences
  • Nanomerics
  • NEUWAY Pharma
  • Ossianix
  • Reglagene
  • Tranquis Therapeutics

You can Download Free Sample PDF Copy of this Report at: 

https://www.rootsanalysis.com/reports/blood-brain-barrier-drug-delivery/310.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry